| DB ID | MyCo_3254 |
| Title | Evaluation of the clinical cutoff level of serum (1 --> 3)-beta-D-glucan in patients with connective tissue diseases complicated by deep fungal infections |
| Year | 2010 |
| PMID | 20349101 |
| Fungal Diseases involved | Invasive fungal infection |
| Associated Medical Condition | connective tissue diseases |
| Genus | None |
| Species | None |
| Organism | None |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Japan |
| Cohort | The clinical data of 229 inpatients with CTDs whose serum levels of (1 ? 3)-b-D-glucan had been measured in our department between June and October 2004 were evalu- ated. Diagnosis of fungal infection was made retrospec- tively, based on the diagnostic criteria established by the European Organization for Research and Treatment of Cancer and the Mycoses Study Group. |
| Cohort No. | 229 |
| Age Group | 54.9 ± 16.8 |
| P Value | None |
| Sensitivity | 0.923 |
| Specificity | 0.813 |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | ELISA |
| Analysis Method | FDA Approved-Fungitell assay |
| ELISA kits | None |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | FDA Approved-Fungitell assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
